1. Home
  2. TSI vs NBTX Comparison

TSI vs NBTX Comparison

Compare TSI & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TCW Strategic Income Fund Inc.

TSI

TCW Strategic Income Fund Inc.

HOLD

Current Price

$4.47

Market Cap

219.6M

Sector

Finance

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$35.23

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSI
NBTX
Founded
1987
2003
Country
United States
France
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
219.6M
1.8B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
TSI
NBTX
Price
$4.47
$35.23
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
134.4K
49.3K
Earning Date
01-01-0001
03-31-2026
Dividend Yield
7.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$58.17
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.43
$4.57
52 Week High
$5.06
$57.14

Technical Indicators

Market Signals
Indicator
TSI
NBTX
Relative Strength Index (RSI) 42.05 43.66
Support Level $4.43 $30.15
Resistance Level $4.58 $41.89
Average True Range (ATR) 0.04 2.61
MACD -0.00 -0.14
Stochastic Oscillator 23.08 54.77

Price Performance

Historical Comparison
TSI
NBTX

About TSI TCW Strategic Income Fund Inc.

Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: